Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study.
Oct 2026· The Lancet Rheumatology· 1 citation· 29 references
Medicine
TL;DR
Long-term follow-up data after autologous HSCT in patients with systemic sclerosis is provided allowing robust assessment of response rate, late complications, and sustained treatment benefit, and might serve as an important comparator for all upcoming, cellular treatment options.
Abstract
Background
Systemic sclerosis is a rare and heterogeneous chronic autoimmune disease. It has the highest mortality of the rheumatic diseases and few treatment options exist. Autologous haematopoietic stem-cell transplantation (HSCT) is an effective and established therapeutic option in selected patients with early severe systemic sclerosis. This study aimed to evaluate the long-term safety and effectiveness of autologous HSCT in patients with systemic sclerosis in real-life clinical practice.
Methods
This cohort study (NISSC1-LTE) followed up patients with systemic sclerosis included in the prospective European Society for Blood and Marrow Transplantation NISSC1 study who had undergone their first autologous HSCT for severe progressive systemic sclerosis. Follow-up data were collected from 13 participating centres in France, Germany, Netherlands, Italy, Spain, Switzerland, and Brazil. Participating centres completed a yearly case report form for each patient alive after 2 years and up to 10 years after autologous HSCT. The primary endpoint was progression-free survival, defined as survival from baseline without evidence of systemic sclerosis progression. Late complications after autologous HSCT, including malignancies, secondary autoimmune diseases, infections, and major adverse cardiovascular events were also analysed. People with lived experience of systemic sclerosis were involved in the design and conduct of this study. The NISSC1 study is registered with ClinicalTrials.gov (NCT02516124) and is complete.
Findings
All 80 patients with systemic sclerosis who had an autologous HSCT between Dec 4, 2012, and Jan 19, 2016, were included in this long-term extension study. 12 patients were lost to follow-up, including five patients with a follow-up less than 5 years. Median age at autologous HSCT was 43 years (IQR 33-51), 57 (71%) of 80 patients were female, 23 (29%) were male, and median follow-up was 9·2 years (IQR 8·9-9·6) after autologous HSCT. Progression-free survival was 81% (95% CI 71-88) at 2 years, 72% (61-81) at 5 years, and 60% (47-71) at 10 years. 18 patients died during the study; causes of death were autologous HSCT-related in five (6%) of 80 patients, disease progression in nine (11%) patients, post-autologous HSCT malignancy in two (3%) patients, and late serious infection in two (3%) patients. 34 (43%) of 80 patients maintained remission without immunosuppressive treatment over 10 years.
Interpretation
This study provides long-term follow-up data after autologous HSCT in patients with systemic sclerosis allowing robust assessment of response rate, late complications, and sustained treatment benefit. The extended timeframe might serve as an important comparator for all upcoming, cellular treatment options.
ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA and its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs.
A. Setzer, S. Dindayal, J. Damelin et al.· South African Medical Journa...· 0 citations
BACKGROUND
Systemic sclerosis (SSc) is a debilitating autoimmune connective tissue disease associated with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (HSCT) improves survival in diffuse cutaneous SSc. Cytokine release syndrome (CRS), a potentially fatal inflammatory response, is a...
Charlotte S. Schimmel, E. Hoekstra, M. Koops et al.· Seminars in Arthritis & Rheu...· 0 citations
BACKGROUND
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for malignant and non-malignant diseases; however, primary graft failure (GF) is a life-threatening complication, particularly with the increasing use of alternative donors and reduced-intensity conditioning (RIC) str...
M. Daniel, Melissa Panesso Romero, María Isabel Benítez Carabante et al.· Transplantation and Cellular...· 0 citations
Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor-derived T cells to mediate the graft-versus-tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T-cell exhaustion. This prospective phase I study evaluated the safety and efficacy...
T. Ngo, E. Wong, Joanne E. Davis et al.· British Journal of Haematolo...· 0 citations
Continuous advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) have led to a growing population of long-term survivors. The Long-Term Follow-Up (LTFU) - typically defined as starting beyond two years post-transplant - aims to prevent, detect, and manage late complications, which progressively rep...
Tereza Coman, Fabio Andreozzi, Alexis Caudron et al.· Bulletin du Cancer· 0 citations
LT is a feasible option for selected patients with end-stage LONIPCs, with long-term survival comparable to that reported for LT performed for other indications, and HLA-mismatched donor transplantation and corticosteroid use at LT were associated with inferior survival.
J. Montoro, S. Bos, C. Peczynski et al.· Bone Marrow Transplantation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.